SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge🤖Agents🚦Status📑Docs
Info
ℹHow it Works🎨Pitch⭐Showcase📽Demo

🎯 Drug Targets

Browse 11 drug targets with druggability analysis, composite scores, and clinical context

11
Targets
0
High Druggability
0.58
Avg Score
15
Target Classes
Druggability Distribution
High: 0Medium: 3Low: 7Unknown: 0
Avg druggability score: 0.406
Clinical Pipeline
Approved: 5Phase III: 1Phase II: 2Phase I: 3Preclinical: 0
Total compounds: 39 · Approved: 18
Class All Classes Enzyme (35) Signaling Protein (25) Structural Protein (17) Protein (16) Gpcr (13) Ion Channel (12) Transcription Factor (11) Receptor (11) Ligand (10) Transporter (8) Epigenetic Regulator (8) Kinase (7) Protease (4) Other (4) Chaperone (4)
Druggability Low (100) Medium (62) High (14) Undruggable (6) other (3)
Sort Score Druggability Gene A-Z Market Price
Filtered by: class=transcription_factor — 11 results
NR3C1 Glucocorticoid receptor Phase 4
Transcription Factor Medium Druggability
Score
0.66
Drug.
0.53
Safety
0.40
Drugs
13
Hyps
1
Papers
18
Selective glucocorticoid receptor modulators (SRMs) or antagonists
AHR Aryl hydrocarbon receptor Phase 2
Transcription Factor Low Druggability
Score
0.65
Drug.
0.35
Safety
0.40
Drugs
2
Hyps
4
Papers
0
Small molecule modulators affecting ligand-dependent transcriptional activity
PPARGC1A Peroxisome proliferator-activated receptor gamma c Phase 4
Transcription Factor Low Druggability
Score
0.59
Drug.
0.43
Safety
0.40
Drugs
3
Hyps
3
Papers
49
Small molecule modulator of transcriptional coactivator function
SREBF2 Sterol regulatory element binding transcription fa Phase 2
Transcription Factor Undruggable Druggability
Score
0.59
Drug.
0.20
Safety
0.30
Drugs
2
Hyps
1
Papers
0
Small molecule modulators of transcriptional activity or protein-protein interactions
TFAM Transcription factor A, mitochondrial Phase 4
Transcription Factor Medium Druggability
Score
0.59
Drug.
0.50
Safety
0.40
Drugs
4
Hyps
9
Papers
28
Drugs targeting TFAM would enhance or modulate its transcriptional activity to increase mitochondrial DNA replication and gene expression, thereby boosting mitochondrial biogenesis and ATP production. Alternatively, indirect approaches activate upstream regulators like PGC-1α and SIRT1 to increase TFAM expression and activity.
FOXO3 Forkhead box protein O3 Phase 4
Transcription Factor Low Druggability
Score
0.58
Drug.
0.42
Safety
0.35
Drugs
4
Hyps
3
Papers
36
FOXO3-targeting drugs modulate the PI3K/Akt/FOXO3 signaling pathway to promote FOXO3 nuclear translocation and transcriptional activity, enhancing autophagy, stress resistance, and apoptosis in cancer cells. Indirect activators increase FOXO3 expression or prevent its degradation, thereby amplifying cellular protective responses.
BMAL1 Basic Helix-Loop-Helix ARNT Like 1 Phase 1
Transcription Factor Low Druggability
Score
0.58
Drug.
0.34
Safety
0.30
Drugs
4
Hyps
11
Papers
29
Small molecule modulator of circadian transcription
FOXO1 Forkhead box protein O1 Phase 1
Transcription Factor Medium Druggability
Score
0.58
Drug.
0.55
Safety
0.30
Drugs
3
Hyps
1
Papers
28
Small molecule modulation of protein-DNA interactions or cofactor binding
CLOCK Circadian Locomotor Output Cycles Kaput Phase 4
Transcription Factor Low Druggability
Score
0.54
Drug.
0.35
Safety
0.40
Drugs
1
Hyps
14
Papers
81
Modulation of circadian transcriptional activity through protein-protein interaction disruption
TARDBP TAR DNA-binding protein 43 Phase 3
Transcription Factor Low Druggability
Score
0.51
Drug.
0.43
Safety
0.20
Drugs
1
Hyps
6
Papers
57
RNA-binding and transcription regulation, challenging for small molecule targeting
FOXP3 Forkhead box protein P3 Phase 1
Transcription Factor Low Druggability
Score
0.49
Drug.
0.35
Safety
0.30
Drugs
2
Hyps
1
Papers
18
Transcription factor modulation - no direct small molecule binding
Exchange | Dashboard